These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31520446)

  • 1. Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease.
    Araki SI
    J Diabetes Investig; 2020 Jan; 11(1):22-24. PubMed ID: 31520446
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
    Reid T
    J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose lowering and the kidney: are all drug classes equal?
    Wong MG; Jardine M; Perkovic V
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
    [No Abstract]   [Full Text] [Related]  

  • 5. Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?
    Martinez Martinez-Castelao A; Soler MJ; Navarro-González JF; Górriz JL
    Nefrologia (Engl Ed); 2019; 39(1):3-10. PubMed ID: 30290959
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor approaches.
    Bloomgarden Z
    J Diabetes; 2017 Jan; 9(1):5-7. PubMed ID: 27576300
    [No Abstract]   [Full Text] [Related]  

  • 7. Light of dawn in Melbourne: SONAR and CREDENCE.
    Nangaku M
    Kidney Int; 2019 Jul; 96(1):2-4. PubMed ID: 31229029
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
    Barutta F; Bernardi S; Gargiulo G; Durazzo M; Gruden G
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3171. PubMed ID: 30997935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.
    Hasan AA; Hocher B
    J Mol Endocrinol; 2017 Jul; 59(1):R1-R10. PubMed ID: 28420715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
    Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
    Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 17. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
    Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
    Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.